Disclaimer: Note that the firm is no longer accepting cases for the anti-psychotic medication Abilify or Tylenol autism cases. Thank you.
Select Page

This is Michael Brady Lynch, lead trial attorney for The Michael Brady Lynch Firm.
There are rare times when you get the opportunity to be part of legal history. As a member of the Bellwether Committee for Xarelto cases, I am assisting with the charge to make this multidistrict litigation a historic landmark of justice.
Xarelto has been responsible for numerous deaths and horrible side effects. It was introduced by Bayer and Johnson & Johnson’s Janssen Pharmaceuticals in 2011, as part of a new generation of anticoagulants promoted as a superior alternative to Coumadin (warfarin), which has been the go-to blood thinner for prevention of strokes among patients with atrial fibrillation for a decade. Currently, there are approximately 13 million active prescriptions.
While all blood thinners carry a risk of bleeding problems, Xarelto lacks an approved antidote. Doctors need an antidote to reverse the effects of the drug. While doctors can quickly stop the blood thinning effects of warfarin, users of Xarelto have reported experiencing uncontrollable bleeding.  Physicians are unable to stop the bleeding. This leads to severe injury or death.
Finally, plaintiffs awaiting justice for years after experiencing the devastating effects of Xarelto are closer to their day in court. August has been a whirlwind of activity. Judges scheduled four trials for February of 2017. Both sides have completed discovery, arguments, and strikes in all four trials. We have been pushing to make sure that Bayer along with Janssen Pharmaceuticals understands the gravity of their actions. The fact is most people should have never switched from warfarin in the first place.
The new science is also supporting our claims that Xarelto is not better than warfarin, and it is actually worse in many cases. The newest study done by the Institute For Safe Medication Practices (ISMP) examined all the adverse events reported to the FDA after patients took the coagulant. They determined that Xarelto failed to prevent pulmonary embolism, caused uncontrollable bleeding, and wasn’t very efficient.
Also, the most troubling piece of information researchers uncovered was 80.9% of the complaints involved an adverse bleeding event. Plus, there were 1,121 deaths.

Still Accepting New Xarelto Cases

At The Michael Brady Lynch Firm, we take these bleeding side effects very seriously. We fight to make sure that pharmaceutical companies understand the seriousness as well. If you or a loved one have experienced a bleeding event from taking Xarelto, I urge you to contact us at 877-513-9517. Let us fight for you.

What Our Clients Are Saying